TLR7 and neoplasm: Here, we report DSP-0509 as a novel intravenous injectable small molecule TLR7 agonist which is designed to be rapidly excrete from body to reduce side effects as well as strong anti-tumor activity additively or synergistically combined with immune checkpoint blockers.